2007
January 17
The NL003 project was selected as a topic under the 2006 “Haidian Park Special Development Fund—Special Fund for the Internationalization of Small and Medium-sized Enterprises.”
February 9
The NL002IIa clinical trial has been successfully completed.
May 30
The Phase IIb clinical trial for NL002 has been fully launched.
July 1
The NL003 project has passed the drug registration inspection conducted by the China National Institute for Drug and Biological Products Control.



